Median (range) concentration of cefotaxime at 5 min after intraosseous administration was 200 mg/l (135 260) compared with 183 mg/l (161 201) after intravenous administration.
The median (range) concentration of mycolactone by mass spectrometry at the centre was 110 ng/ml (18-285), significantly higher than 26 ng/ml (0-75) athehe periphery (p < 0.05).
The median (range) concentration of mycolactone in 80 untreated lesions measured by mass spectrometry was 26 ng/ml (0-1970), significantlowerwer than that measured by cytotoxicity at 439 ng/ml (136 3020) (p < 0.0001).
High plasma levels of both enantiomers were observed in some individuals, with median (range) concentrations of 8.2 (0.6-24.8) and 20.6 (0.5-57.3) ng/mL for (R)- and (S)- albuterol respectively among acute asthma subjects, and 2.1 (0.0-16.7) to 4.1 (0.0-36.1) ng/mL for (R)- and (S)- albuterol respectively among COPD subjects.
Saquinavir median (range) concentrations were < 2.5 (< 2.5 96.0) nM unbound in plasma, and < 2.5 (< 2.5 9.0) nM total in CSF.
Nelfinavir median (range) concentrations were 10.0 (< 2.0 31.0) nM unbound in plasma, and < 2.0 (< 2.0 23.0) nM total in CSF.
Saquinavir and nelfinavir median (range) concentrations in plasma and CSF are shown in Table 2. Saquinavir and nelfinavir were detectable in 7 out of 15, and 9 out of 15 CSF samples, respectively.
Following the first vaccination, the SAA concentration in all groups reached a peak 24 hours after vaccination (day 1) with median (range) concentrations of 407 (156–770) mg/L, 411 (153–755) mg/L and 455 (147–765) mg/L for the HH, HL and LH maternal nutrition groups respectively.
After the second vaccination, the SAA concentration in all groups also reached a peak 24 hours after vaccination with median (range) concentrations of 175 (54–357) mg/L, 105 (44–481) mg/L and 125 (80–260) mg/L for the HH, HL and LH nutrition groups respectively.
Following the first vaccination, the serum Hp concentration in all groups reached a peak at 24 hours after vaccination (day 1) with median (range) concentrations of 0.11 (0.05–0.43) g/L, 0.10 (0.05–0.29) g/L and 0.12 (0.06–0.31) g/L for the HH, HL and LH nutrition groups respectively.
Following the second vaccination, the serum Hp concentration in all groups reached a peak 24 or 48 hours after vaccination with median (range) concentrations of 0.13 (0.02–0.57) g/L, 0.175 (0.02–0.47) g/L and 0.06 (0.02–0.21) g/L for the HH (48 h), HL (48 h) and LH (24 h) nutrition groups respectively.
